VDAC1: A Potential Drug Target and Biomarker for voltage-dependent anion-selective channel protein 1 (ISOform 1)

Target Name: VDAC1

NCBI ID: G7416

VDAC1

VDAC1: A Potential Drug Target and Biomarker for voltage-dependent anion-selective channel protein 1 (ISOform 1)

Voltage-dependent anion-selective channel protein 1 (VDAC1) is a protein that plays a crucial role in the regulation of ion channels in various organisms, including humans. It is a member of the subfamily of voltage-dependent anion channels (VDAC), which are involved in the regulation of proton channels that play a vital role in various physiological processes, including neurotransmitter signaling, intracellular signaling, and pharmacological drug action. VDAC1 is expressed in most tissues and cells of the body and is involved in the regulation of a wide range of physiological processes, including neuronal excitability, neurotransmission, and the regulation of ion channels in various organs and tissues.

In addition to its role in ion channel regulation, VDAC1 is also a potential drug target and biomarker. Its unique voltage-dependent anion-selectivity has been identified as a potential drug target, and several studies have demonstrated its potential as a drug target for various diseases, including neurodegenerative disorders, pain, and cardiomyopathy. In this article, we will discuss the potential of VDAC1 as a drug target and biomarker, as well as its current status as a drug target and the research that is being conducted to investigate its potential.

Potential Drug Target

VDAC1 has been identified as a potential drug target due to its unique voltage-dependent anion-selectivity. This property makes VDAC1 an attractive target for drugs that aim to modulate ion channels and improve neuronal excitability. Several studies have demonstrated that modulation of VDAC1 channels can have a significant impact on neuronal function and behavior, including changes in neurotransmitter release, action potential generation, and synaptic plasticity.

One of the main advantages of VDAC1 as a drug target is its widespread distribution in the brain and its potential to modulate ion channels in a variety of neurotransmitter systems. This makes it an attractive target for drugs that aim to treat a wide range of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, VDAC1 channels have been shown to play a crucial role in the regulation of pain perception and neurotransmission, making them an attractive target for drugs that aim to alleviate pain.

Biomarker

VDAC1 has also been identified as a potential biomarker for several diseases, including neurodegenerative disorders, pain, and cardiomyopathy. Its voltage-dependent anion-selectivity makes it an attractive biomarker for these diseases, as changes in VDAC1 channels can be used as a diagnostic or therapeutic target.

One of the main advantages of VDAC1 as a biomarker is its potential to be used for early disease detection. Its voltage-dependent anion-selectivity makes it an attractive target for diagnostic tools that aim to measure changes in ion channels in response to specific therapeutic interventions. This has the potential to revolutionize the field of neurodegenerative disorders, allowing for earlier detection and treatment of these diseases.

Current Research

Several studies have been conducted to investigate the potential of VDAC1 as a drug target and biomarker. These studies have focused on the modulation of VDAC1 channels in response to various therapeutic interventions, including pharmacological agents, behavioral interventions, and electrical stimulation.

One of the main challenges in studying VDAC1 as a drug target is its complex structure and function. Its voltage-dependent anion-selectivity is determined by several unique amino acid residues, which makes it difficult to study. Additionally, its widespread distribution in the brain makes it difficult to study its effects in a controlled manner.

Despite these challenges, several studies have demonstrated the potential of VDAC1 as a drug target and biomarker. For example, several studies have shown that modulation

Protein Name: Voltage Dependent Anion Channel 1

Functions: Forms a channel through the mitochondrial outer membrane and also the plasma membrane. The channel at the outer mitochondrial membrane allows diffusion of small hydrophilic molecules; in the plasma membrane it is involved in cell volume regulation and apoptosis. It adopts an open conformation at low or zero membrane potential and a closed conformation at potentials above 30-40 mV. The open state has a weak anion selectivity whereas the closed state is cation-selective (PubMed:11845315, PubMed:18755977, PubMed:20230784, PubMed:8420959). Binds various signaling molecules, including the sphingolipid ceramide, the phospholipid phosphatidylcholine, and the sterol cholesterol (PubMed:31015432). In depolarized mitochondria, acts downstream of PRKN and PINK1 to promote mitophagy or prevent apoptosis; polyubiquitination by PRKN promotes mitophagy, while monoubiquitination by PRKN decreases mitochondrial calcium influx which ultimately inhibits apoptosis (PubMed:32047033). May participate in the formation of the permeability transition pore complex (PTPC) responsible for the release of mitochondrial products that triggers apoptosis (PubMed:15033708, PubMed:25296756). May mediate ATP export from cells (PubMed:30061676)

The "VDAC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VDAC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets